Brain cancer patients get continued access to promising combo therapy in long-term safety study

NCT ID NCT07569042

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to an experimental drug (NBM-BMX) plus standard chemotherapy (temozolomide) for people with newly diagnosed glioblastoma, a serious brain cancer, who completed a previous trial. About 15 participants will be monitored for long-term safety and how well the treatment controls the disease. The goal is to see if the combination remains safe and helps keep the cancer from growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, 807, Taiwan

    Contact Phone: •••-•••-••••

  • Linkou Chang-Gung Memorial Hospital

    RECRUITING

    Taoyuan City, 333, Taiwan

    Contact Phone: •••-•••-••••

  • Taichung Veterans General Hospital

    NOT_YET_RECRUITING

    Taichung, 407, Taiwan

    Contact Phone: •••-•••-••••